Incyte Co. (NASDAQ:INCY) – Equities researchers at Gabelli boosted their FY2020 earnings estimates for shares of Incyte in a note issued to investors on Wednesday. Gabelli analyst J. He now expects that the biopharmaceutical company will post earnings per share of $4.35 for the year, up from their previous forecast of $4.30.
Incyte (NASDAQ:INCY) last posted its earnings results on Tuesday, October 31st. The biopharmaceutical company reported $0.17 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.06 by $0.11. The firm had revenue of $381.50 million during the quarter, compared to analyst estimates of $360.34 million. Incyte had a negative net margin of 10.90% and a negative return on equity of 12.91%. Incyte’s revenue was up 41.6% on a year-over-year basis. During the same period in the previous year, the business posted $0.19 EPS.
Incyte (NASDAQ INCY) traded up $1.24 during trading on Friday, reaching $93.16. 1,912,640 shares of the company’s stock were exchanged, compared to its average volume of 1,590,000. The company has a debt-to-equity ratio of 0.01, a current ratio of 4.82 and a quick ratio of 4.81. The firm has a market cap of $19,660.00, a price-to-earnings ratio of -116.45 and a beta of 0.74. Incyte has a 52-week low of $88.81 and a 52-week high of $153.15.
Several hedge funds have recently added to or reduced their stakes in INCY. Riverhead Capital Management LLC raised its holdings in shares of Incyte by 22.0% during the second quarter. Riverhead Capital Management LLC now owns 3,030 shares of the biopharmaceutical company’s stock valued at $381,000 after acquiring an additional 546 shares during the period. Seven Eight Capital LP acquired a new stake in shares of Incyte during the second quarter valued at approximately $129,000. Ameriprise Financial Inc. raised its holdings in shares of Incyte by 6.3% during the second quarter. Ameriprise Financial Inc. now owns 228,079 shares of the biopharmaceutical company’s stock valued at $28,722,000 after acquiring an additional 13,564 shares during the period. PNC Financial Services Group Inc. raised its holdings in shares of Incyte by 17.1% during the second quarter. PNC Financial Services Group Inc. now owns 36,123 shares of the biopharmaceutical company’s stock valued at $4,549,000 after acquiring an additional 5,284 shares during the period. Finally, Rafferty Asset Management LLC raised its holdings in shares of Incyte by 55.8% during the second quarter. Rafferty Asset Management LLC now owns 12,111 shares of the biopharmaceutical company’s stock valued at $1,525,000 after acquiring an additional 4,340 shares during the period. Institutional investors and hedge funds own 90.76% of the company’s stock.
In other news, EVP Vijay K. Iyengar sold 5,000 shares of the business’s stock in a transaction that occurred on Tuesday, January 2nd. The shares were sold at an average price of $97.26, for a total transaction of $486,300.00. The transaction was disclosed in a document filed with the SEC, which is accessible through this link. Also, insider David W. Gryska sold 6,760 shares of the business’s stock in a transaction that occurred on Friday, January 5th. The shares were sold at an average price of $98.87, for a total transaction of $668,361.20. Following the sale, the insider now owns 20,752 shares in the company, valued at approximately $2,051,750.24. The disclosure for this sale can be found here. Insiders sold a total of 44,878 shares of company stock worth $4,636,494 over the last quarter. Insiders own 17.70% of the company’s stock.
COPYRIGHT VIOLATION NOTICE: “Brokers Issue Forecasts for Incyte Co.’s FY2020 Earnings (INCY)” was originally posted by Ticker Report and is owned by of Ticker Report. If you are accessing this piece of content on another domain, it was illegally copied and reposted in violation of U.S. & international trademark and copyright law. The legal version of this piece of content can be accessed at https://www.tickerreport.com/banking-finance/3146606/brokers-issue-forecasts-for-incyte-co-s-fy2020-earnings-incy.html.
Incyte Company Profile
Incyte Corporation is a biopharmaceutical company focused on the discovery, development and commercialization of therapeutics. Its portfolio includes compounds in various stages, ranging from preclinical to late-stage development, and commercialized products, such as JAKAFI (ruxolitinib) and ICLUSIG (ponatinib).
Receive News & Ratings for Incyte Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Incyte and related companies with MarketBeat.com's FREE daily email newsletter.